LTS congratulates its partner TEVA Pharmaceutical Industries for the US launch of ZECUITY®, a transdermal patch system for the treatment of acute migraine.

Approximately 36 million people in the US suffer from migraines and characteristics such as throbbing pain, sensitivity to light, sensitivity to sound and nausea.

ZECUITY® is a prescription medicine used for the acute treatment of migraine with or without aura in adults.

As TEVA’s partner, LTS contributed to the development of ZECUITY®. LTS produces ZECUITY® in its production sites in Andernach, Germany, and West Caldwell, US.